Literature DB >> 22664785

Parkinson disease: Serotonin reuptake inhibitors for depression in PD.

Santiago Perez-Lloret, Olivier Rascol.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22664785     DOI： 10.1038/nrneurol.2012.111

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN： 1759-4758            Impact factor:   42.937


× No keyword cloud information.
  10 in total

1.  Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial.

Authors:  Paolo Barone; Werner Poewe; Stefan Albrecht; Catherine Debieuvre; Dan Massey; Olivier Rascol; Eduardo Tolosa; Daniel Weintraub
Journal:  Lancet Neurol       Date:  2010-05-07       Impact factor: 44.182

2.  Depression rating scales in Parkinson's disease: critique and recommendations.

Authors:  Anette Schrag; Paolo Barone; Richard G Brown; Albert F G Leentjens; William M McDonald; Sergio Starkstein; Daniel Weintraub; Werner Poewe; Olivier Rascol; Cristina Sampaio; Glenn T Stebbins; Christopher G Goetz
Journal:  Mov Disord       Date:  2007-06-15       Impact factor: 10.338

Review 3.  Drug-induced parkinsonism: a review of 17 years' experience in a regional pharmacovigilance center in France.

Authors:  Emmanuelle Bondon-Guitton; Santiago Perez-Lloret; Haleh Bagheri; Christine Brefel; Olivier Rascol; Jean-Louis Montastruc
Journal:  Mov Disord       Date:  2011-06-14       Impact factor: 10.338

Review 4.  Depression in Parkinson disease--epidemiology, mechanisms and management.

Authors:  Dag Aarsland; Sven Påhlhagen; Clive G Ballard; Uwe Ehrt; Per Svenningsson
Journal:  Nat Rev Neurol       Date:  2011-12-26       Impact factor: 42.937

Review 5.  The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease.

Authors:  Klaus Seppi; Daniel Weintraub; Miguel Coelho; Santiago Perez-Lloret; Susan H Fox; Regina Katzenschlager; Eva-Maria Hametner; Werner Poewe; Olivier Rascol; Christopher G Goetz; Cristina Sampaio
Journal:  Mov Disord       Date:  2011-10       Impact factor: 10.338

6.  A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease.

Authors:  I H Richard; M P McDermott; R Kurlan; J M Lyness; P G Como; N Pearson; S A Factor; J Juncos; C Serrano Ramos; M Brodsky; C Manning; L Marsh; L Shulman; H H Fernandez; K J Black; M Panisset; C W Christine; W Jiang; C Singer; S Horn; R Pfeiffer; D Rottenberg; J Slevin; L Elmer; D Press; H C Hyson; W McDonald
Journal:  Neurology       Date:  2012-04-11       Impact factor: 9.910

7.  Blinding in randomised trials: hiding who got what.

Authors:  Kenneth F Schulz; David A Grimes
Journal:  Lancet       Date:  2002-02-23       Impact factor: 79.321

Review 8.  Efficacy and acceptability of selective serotonin reuptake inhibitors for the treatment of depression in Parkinson's disease: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Petros Skapinakis; Eleni Bakola; Georgia Salanti; Glyn Lewis; Athanasios P Kyritsis; Venetsanos Mavreas
Journal:  BMC Neurol       Date:  2010-06-21       Impact factor: 2.474

9.  A controlled trial of antidepressants in patients with Parkinson disease and depression.

Authors:  M Menza; R D Dobkin; H Marin; M H Mark; M Gara; S Buyske; K Bienfait; A Dicke
Journal:  Neurology       Date:  2008-12-17       Impact factor: 9.910

Review 10.  Selegiline transdermal system: a novel treatment option for major depressive disorder.

Authors:  Jayasree J Nandagopal; Melissa P DelBello
Journal:  Expert Opin Pharmacother       Date:  2009-07       Impact factor: 3.889
  10 in total
  5 in total

Review 1.  Monoamine reuptake inhibitors in Parkinson's disease.

Authors:  Philippe Huot; Susan H Fox; Jonathan M Brotchie
Journal:  Parkinsons Dis       Date:  2015-02-25

2.  Methylphenidate : a treatment for Parkinson's disease?

Authors:  David Devos; Caroline Moreau; Arnaud Delval; Kathy Dujardin; Luc Defebvre; Regis Bordet
Journal:  CNS Drugs       Date:  2013-01       Impact factor: 5.749

Review 3.  Is Dysregulation of the HPA-Axis a Core Pathophysiology Mediating Co-Morbid Depression in Neurodegenerative Diseases?

Authors:  Xin Du; Terence Y Pang
Journal:  Front Psychiatry       Date:  2015-03-09       Impact factor: 4.157

4.  Mirtazapine has a therapeutic potency in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced mice model of Parkinson's disease.

Authors:  Naoto Kadoguchi; Shinji Okabe; Yukio Yamamura; Misaki Shono; Tatsuya Fukano; Akie Tanabe; Hironori Yokoyama; Jiro Kasahara
Journal:  BMC Neurosci       Date:  2014-06-25       Impact factor: 3.288

5.  Influence of depressive symptoms on dopaminergic treatment of Parkinson's disease.

Authors:  Alexandru Hanganu; Clotilde Degroot; Oury Monchi; Christophe Bedetti; Béatriz Mejia-Constain; Anne-Louise Lafontaine; Sylvain Chouinard; Marie-Andrée Bruneau
Journal:  Front Neurol       Date:  2014-09-25       Impact factor: 4.003
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.